Single-center experience with nivolumab in pretreated patients with non-small cell lung cancer (NSCLC).
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.7_suppl.90
Abstract: 90Background: Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, disrupts PD-1-mediated signaling and may restore antitumor immunity in NSCLC patients. Methods: A retrospective review of data from 20 patient records were used… read more here.
Keywords: single center; pts failed; experience nivolumab; center experience ... See more keywords
Experience of nivolumab and pembrolizumab in metastatic non-small cell lung cancer in routine clinical practice (mNSCLC.).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e21227
Abstract: e21227Background: Pembrolizumab (P) in first line if PD-L1 expression > 50% (KEYNOTE-024) or nivolumab (N) in second line (CheckMate 017 and 057) improves overall survival compared to chemotherapy ... read more here.
Keywords: non small; metastatic non; experience nivolumab; nivolumab pembrolizumab ... See more keywords